# Xaira Therapeutics

**Source:** https://geo.sig.ai/brands/xaira-therapeutics  
**Vertical:** Healthcare & Life Sciences  
**Subcategory:** AI Drug Discovery  
**Tier:** Challenger  
**Website:** xaira.com  
**Last Updated:** 2026-04-14

## Summary

AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.

## Company Overview

Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).

Xaira builds AI models predicting biological behavior at the cellular level to design novel therapeutics, initially targeting inflammatory and immunological diseases. X-Cell, unveiled March 2026, predicts gene function from genetic perturbations. Board includes former FDA Commissioner Scott Gottlieb and Nobel laureate Carolyn Bertozzi.

Investors include F-Prime, NEA, Sequoia, Lux Capital, and Lightspeed. Pre-revenue, focused on building AI platform, proprietary datasets, and advancing antibody therapy programs toward clinical development.

## Frequently Asked Questions

### What is Xaira Therapeutics?
AI drug discovery company using ML to design novel therapeutics for inflammatory and immunological diseases. Launched April 2024 with $1B in committed capital.

### Who leads Xaira?
CEO Marc Tessier-Lavigne (ex-Stanford president) and co-founder David Baker (Nobel laureate). Board includes former FDA Commissioner Scott Gottlieb.

### What is X-Cell?
Xaira's AI cell model (March 2026) predicting gene function from genetic perturbations using large-scale cellular data.

### Does Xaira have drugs in trials?
No, still in research/preclinical stage as of early 2026, focused on building its AI platform and antibody therapy programs.

### How much funding does Xaira have?
$1 billion in committed capital from Arch Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia, Lux, and Lightspeed.

### What is Xaira Therapeutics' approach to drug discovery?
Xaira Therapeutics combines generative AI for protein and molecule design with large-scale experimental capabilities to create a vertically integrated AI drug discovery engine—designing novel therapeutic molecules, testing them experimentally, and using the results to continuously improve its AI models in a tight design-build-test loop.

### What diseases does Xaira Therapeutics target?
Xaira focuses on diseases with high unmet medical need where its AI-driven protein design capabilities can create therapeutic molecules (antibodies, biologics, small molecules) that conventional drug discovery approaches have struggled to develop—initially targeting specific mechanisms in oncology and immunology.

### What funding has Xaira raised?
Xaira Therapeutics raised $1 billion at launch in April 2024, one of the largest initial raises in biotech history, from investors including ARCH Venture Partners and Foresite Capital. The company was co-founded by Marc Tessier-Lavigne and assembled a team of leading AI and drug discovery scientists.

## Tags

healthtech, b2b

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*